Recombinant AAV preparations
A composition of rAAV particles, buffer, salt, alcohol, and surfactant optimizes delivery to the central nervous system, enhancing transduction efficiency and distribution for effective gene therapy.
Patent Information
- Application Number
- JP2024509052
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-18
- Filing Date
- 2022-08-18
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2042-08-18
AI Technical Summary
Delivery of recombinant adeno-associated virus (rAAV) vectors to the central nervous system is challenging due to limited transduction efficiency and targeting only cells near the injection site.
A pharmaceutical composition comprising rAAV particles, buffer, monovalent salt, polyhydric alcohol, and triblock copolymer surfactant, optimized with specific concentrations and pH, is used for intrathecal administration to enhance delivery to the central nervous system.
The composition improves transduction efficiency and broader distribution of rAAV vectors within the central nervous system, facilitating effective gene therapy.
Smart Images

Figure 0007954193000003 
Figure 0007954193000004 
Figure 0007954193000005
Abstract
Description
Technical Field
[0001] Cross-Reference to Related Applications This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 234,408, filed August 18, 2021, the entire content of which is incorporated herein by reference in its entirety for all purposes.
[0002] Sequence Listing This application contains a Sequence Listing which is electronically submitted in XML format and is incorporated by reference in its entirety. The XML file (created on August 11, 2022) is named ULP_013WO_SL.xml and has a size of 49 kilobytes.
[0003] Technical Field of the Invention The present disclosure generally relates to compositions comprising recombinant adeno-associated virus vectors and methods of using the same.
Background Art
[0004] Background of the Invention Adeno-associated virus (AAV) is a small non-enveloped virus that packages a linear single-stranded DNA genome. AAV vectors can mediate the transfer of heterologous genes, for example, genes encoding functional proteins for gene therapy. Several recombinant AAV (rAAV) vectors are under development for treating various disorders, such as central nervous system disorders. However, delivery of therapeutic agents to the central nervous system is often difficult. For example, in some circumstances, viral vectors have been observed to transduce only those cells in the vicinity of the injection site, or otherwise exhibit very limited transduction efficiency.
[0005] The present invention addresses this need, for example, by providing compositions for the delivery of rAAV to the central nervous system.
Summary of the Invention
Means for Solving the Problems
[0006] Summary of the Invention The present invention provides compositions comprising recombinant adeno-associated virus (rAAV) and methods of using them. For example, the compositions disclosed herein may be used, for example, to deliver rAAV vectors for gene therapy to the central nervous system.
[0007] In one situation, a) Recombinant adeno-associated virus (rAAV) particles; b) buffer; c) Monovalent salt; d) Polyhydric alcohols; and e) Triblock copolymer surfactants, A pharmaceutical composition containing the following is provided.
[0008] In some embodiments, the above-mentioned pharmaceutical composition has a pH between 7.0 and 7.4, for example, about 7.2.
[0009] In some embodiments, the buffer is a phosphate buffer. In some embodiments, the phosphate is present in the composition at a concentration between 5 mM and 30 mM, for example, about 10 mM.
[0010] In some embodiments, the buffer is a Tris buffer. In some embodiments, Tris is present in the composition at a concentration between 5 mM and 30 mM, for example, about 10 mM.
[0011] In some embodiments, the polyhydric alcohol is a sugar alcohol selected from the group consisting of erythritol, glycerol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol.
[0012] In some embodiments, the sugar alcohol is sorbitol. In some embodiments, sorbitol is present in the composition at a concentration of at least 1% or at least 5%. In some embodiments, sorbitol is present in the composition at a concentration between 0.5% and 20%, for example, between 5% and 10%. In some embodiments, sorbitol is present in the composition at a concentration of about 5%. In some embodiments, sorbitol is present in the composition at a concentration of about 10%.
[0013] In some embodiments, the triblock copolymer surfactant is a copolymer of ethylene oxide (EO) and propylene oxide (PO) (e.g., poloxamer). In some embodiments, the poloxamer is poloxamer 188 (Pluronic® F68). In some embodiments, the poloxamer is present in the composition at a concentration between about 0.0001% and about 0.001%. In some embodiments, the poloxamer is present in the composition at a concentration of at least 0.0001%, at least 0.0005%, or at least 0.001%. In some embodiments, the poloxamer is present in the composition at a concentration of about 0.0001%. In some embodiments, the poloxamer is present in the composition at a concentration of about 0.001%.
[0014] In some embodiments, the polyhydric alcohol is sorbitol, and the triblock copolymer surfactant is poloxamer.
[0015] In some embodiments, the monovalent salt is NaCl, KCl, or a combination thereof.
[0016] In some embodiments, NaCl is present in the composition at a concentration between 100 mM and 250 mM, for example, about 130 mM or about 135 mM.
[0017] In some embodiments, the above pharmaceutical composition comprises NaCl and KCl.
[0018] In some embodiments, KCl is present in the composition at a concentration between 0.5 mM and 5 mM, for example, about 2 mM.
[0019] In some embodiments, the above pharmaceutical composition further comprises one or more divalent salts, such as MgCl2, CaCl2, or a combination thereof.
[0020] In some embodiments, MgCl2 is present in the composition at a concentration between 0.5 mM and 5 mM, for example, about 1 mM.
[0021] In some embodiments, CaCl2 is present in the composition at a concentration between 0.5 mM and 5 mM, for example, at about 1 mM CaCl2.
[0022] In some embodiments, rAAV particles are 1 × 10 10 ~2×10 14 It is present in the above composition at a concentration of GC / mL.
[0023] In some embodiments, the rAAV particles include AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, AAVhu37, or AAV capsids derived from these variants. In some embodiments, the rAAV particles include AAV capsids derived from AAV9.
[0024] For example, in some embodiments, the pharmaceutical compositions of this disclosure are a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphates with concentrations between 5 mM and 30 mM c) NaCl concentrations between 100 mM and 250 mM; d) Sorbitol in concentrations between 1% and 10%; and e) Poloxamer at concentrations between 0.0001% and 0.001%, This composition includes, where the pH is between 7.0 and 7.4.
[0025] In some embodiments, the pharmaceutical compositions of this disclosure are a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphate at a concentration of approximately 10 mM; c) NaCl at a concentration of approximately 135 mM; d) Sorbitol at a concentration of approximately 5%; and e) Poloxamer at a concentration of approximately 0.001%, Includes, Here, the above composition has a pH of approximately 7.2.
[0026] In some embodiments, the pharmaceutical compositions of this disclosure are a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphate at a concentration of approximately 10 mM; c) NaCl at a concentration of approximately 135 mM; d) Sorbitol at a concentration of approximately 10%; and e) Poloxamer at a concentration of approximately 0.001%, Includes, Here, the above composition has a pH of approximately 7.2.
[0027] In some embodiments, the pharmaceutical compositions of this disclosure are a) Recombinant adeno-associated virus (rAAV) particles; b) Tris of concentrations between 5 mM and 30 mM; c) NaCl concentrations between 100 mM and 250 mM; d) KCl concentrations between 0.5 mM and 5 mM; e) MgCl2 at concentrations between 0.5 mM and 5 mM; f) CaCl2 concentrations between 0.5 mM and 5 mM; d) Sorbitol in concentrations between 1% and 10%; and e) Poloxamer at concentrations between 0.0001% and 0.001%, Includes, Here, the above composition has a pH between 7.0 and 7.4.
[0028] In some embodiments, the pharmaceutical compositions of this disclosure are a) Recombinant adeno-associated virus (rAAV) particles; b) Approximately 10mM Tris; c) Approximately 130mM NaCl; d) Approximately 2mM KCl; e) Approximately 1mM MgCl2; f) Approximately 1mM CaCl2; d) Approximately 5% sorbitol; and e) Approximately 0.001% poloxamer, Includes, Here, the above composition has a pH of approximately 7.2.
[0029] In some embodiments, the poloxamer in the pharmaceutical compositions of this disclosure is poloxamer 188 (Pluronic® F68).
[0030] In some embodiments, the rAAV particles include AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, AAVhu37, or AAV capsids derived from these variants. In some embodiments, the rAAV particles include AAV capsids derived from AAV9.
[0031] In some embodiments, the rAAV particles comprise an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises a partial or complete coding sequence of CDKL5, or a functional fragment or variant thereof.
[0032] In some embodiments, the coding sequence of CDKL5 includes a nucleotide sequence selected from SEQ ID NOs. 12-18 and 19, or a nucleotide sequence that is at least 95% identical to any one of SEQ ID NOs. 12-19.
[0033] In some embodiments, the vector genome includes the nucleotide sequence of SEQ ID NO: 20 or a sequence that is at least 95% identical thereto.
[0034] In some embodiments, the above pharmaceutical composition is suitable for intrathecal administration. In some embodiments, the intrathecal administration includes administration into the ventricle, lumbar spine, or cisterna magna.
[0035] In one aspect, a method is provided for delivering rAAV to the central nervous system of a subject, the method comprising the step of administering to the subject a pharmaceutical composition as disclosed herein. In some embodiments, the subject is a mammal.
[0036] In some embodiments, the administration step includes intrathecal administration, such as intraventricular, lumbar, or cisterna magna administration. In some embodiments, the intrathecal administration includes cisterna magna administration. In certain embodiments, for example, the following are provided: (Item 1) a) Recombinant adeno-associated virus (rAAV) particles; b) buffer; c) Monovalent salt; d) Polyhydric alcohols; and e) Triblock copolymer surfactants, A pharmaceutical composition containing [a certain substance]. (Item 2) A pharmaceutical composition as described in item 1, having a pH between 7.0 and 7.4. (Item 3) A pharmaceutical composition as described in item 1, having a pH of approximately 7.2. (Item 4) The buffer is a phosphate buffer, and is a pharmaceutical composition according to any one of items 1 to 3. (Item 5) The phosphate is present in the composition at a concentration between 5 mM and 30 mM, as described in item 4 of the pharmaceutical composition. (Item 6) The phosphate is present in the composition at a concentration of approximately 10 mM, as described in item 5 of the pharmaceutical composition. (Item 7) The aforementioned buffer is Tris buffer, the pharmaceutical composition according to any one of items 1 to 3. (Item 8) The pharmaceutical composition described in item 7, wherein Tris is present in the composition at a concentration between 5 mM and 30 mM. (Item 9) The pharmaceutical composition described in item 8, wherein Tris is present in the composition at a concentration of approximately 10 mM. (Item 10) The pharmaceutical composition according to any one of items 1 to 9, wherein the polyhydric alcohol is a sugar alcohol. (Item 11) The pharmaceutical composition according to item 10, wherein the sugar alcohol is selected from the group consisting of erythritol, glycerol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol. (Item 12) The pharmaceutical composition according to item 11, wherein the sugar alcohol is sorbitol. (Item 13) The pharmaceutical composition according to item 12, wherein sorbitol is present in the composition at a concentration of at least 1%. (Item 14) The pharmaceutical composition according to item 13, wherein sorbitol is present in the composition at a concentration of at least 5%. (Item 15) The pharmaceutical composition according to item 12, wherein sorbitol is present in the composition at a concentration between 0.5% and 20%. (Item 16) The pharmaceutical composition according to item 15, wherein sorbitol is present in the composition at a concentration between 5% and 10%. (Item 17) The pharmaceutical composition according to item 12, wherein sorbitol is present in the composition at a concentration of approximately 5%. (Item 18) The pharmaceutical composition according to item 12, wherein sorbitol is present in the composition at a concentration of approximately 10%. (Item 19) The pharmaceutical composition according to any one of items 1 to 18, wherein the triblock copolymer surfactant is a copolymer of ethylene oxide (EO) and propylene oxide (PO). (Item 20) The pharmaceutical composition according to item 19, wherein the triblock copolymer surfactant is a poloxamer. (Item 21) The poloxamer is poloxamer 188 (Pluronic® F68), as described in item 20, for the pharmaceutical composition. (Item 22) The polixamer is present in the composition at a concentration between 0.0001% and approximately 0.001% in the pharmaceutically acceptable composition according to item 20 or 21. (Item 23) The polixamer is present in the composition at a concentration of at least 0.0001% in the pharmaceutically acceptable composition according to item 20 or 21. (Item 24) The pharmaceutically acceptable composition according to item 23, wherein the poloxamer is present in the composition at a concentration of at least 0.0005%. (Item 25) The polixamer is present in the composition at a concentration of at least 0.001% in the pharmaceutical composition according to item 24. (Item 26) The poloxamer is present in the composition at a concentration of approximately 0.0001% in the pharmaceutical composition as described in item 21. (Item 27) The poloxamer is present in the composition at a concentration of approximately 0.001% in the pharmaceutical composition as described in item 21. (Item 28) The pharmaceutical composition according to any one of items 1 to 27, wherein the polyhydric alcohol is sorbitol and the triblock copolymer surfactant is poloxamer. (Item 29) The monovalent salt is NaCl, KCl, or a combination thereof, as described in any one of items 1 to 28 of the pharmaceutical composition. (Item 30) The pharmaceutical composition described in item 29, wherein NaCl is present in the composition at a concentration between 100 mM and 250 mM. (Item 31) The pharmaceutical composition described in item 29, wherein NaCl is present in the composition at a concentration of approximately 130 mM. (Item 32) The pharmaceutical composition described in item 29, wherein NaCl is present in the composition at a concentration of approximately 135 mM. (Item 33) A pharmaceutical composition comprising NaCl and KCl, as described in any one of items 1 to 32. (Item 34) The pharmaceutical composition according to any one of items 1 to 33, wherein KCl is present in the composition at a concentration between 0.5 mM and 5 mM. (Item 35) The pharmaceutical composition described in item 34, wherein KCl is present in the composition at a concentration of approximately 2 mM. (Item 36) A pharmaceutical composition according to any one of items 1 to 35, further comprising one or more divalent salts. (Item 37) The aforementioned divalent salt is MgCl 2 CaCl 2 A pharmaceutical composition as described in item 36, selected from the group consisting of these and combinations thereof. (Item 38) MgCl 2 The pharmaceutical composition described in item 37, wherein the substance is present in the composition at a concentration between 0.5 mM and 5 mM. (Item 39) MgCl 2 The pharmaceutical composition described in item 38, wherein the substance is present in the composition at a concentration of approximately 1 mM. (Item 40) CaCl 2 The pharmaceutical composition described in any one of items 37 to 39, wherein the compound is present in the composition at a concentration between 0.5 mM and 5 mM. (Item 41) CaCl 2 It is approximately 1 mM CaCl 2 The pharmaceutical composition described in item 40, which is present in the composition at the concentration of [amount]. (Item 42) rAAV particles are 1 × 10⁻⁶ 10 ~2×10 14 A pharmaceutical composition according to any one of items 1 to 41, present in the composition at a concentration between GC / mL. (Item 43) The rAAV particles comprise AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, AAVhu37, or AAV capsids derived from these variants, as described in any one of items 1 to 42. (Item 44) The rAAV particles are a pharmaceutical composition according to item 43, comprising an AAV capsid derived from AAV9. (Item 45) a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphates at concentrations between 5 mM and 30 mM; c) NaCl concentrations between 100 mM and 250 mM; d) Sorbitol in concentrations between 1% and 10%; and e) Poloxamer at concentrations between 0.0001% and 0.001%, A pharmaceutical composition containing, Here, the composition is a pharmaceutical composition having a pH between 7.0 and 7.4. (Item 46) a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphate at a concentration of approximately 10 mM; c) NaCl at a concentration of approximately 135 mM; d) Sorbitol at a concentration of approximately 5%; and e) Poloxamer at a concentration of approximately 0.001%, Includes, Here, the composition is the pharmaceutical composition described in item 45, having a pH of about 7.2. (Item 47) a) Recombinant adeno-associated virus (rAAV) particles; b) Phosphate at a concentration of approximately 10 mM; c) NaCl at a concentration of approximately 135 mM; d) Sorbitol at a concentration of approximately 10%; and e) Poloxamer at a concentration of approximately 0.001%, Includes, Here, the composition is the pharmaceutical composition described in item 45, having a pH of about 7.2. (Item 48) a) Recombinant adeno-associated virus (rAAV) particles; b) Tris of concentrations between 5 mM and 30 mM; c) NaCl concentrations between 100 mM and 250 mM; d) KCl concentrations between 0.5 mM and 5 mM; e) MgCl concentrations between 0.5 mM and 5 mM 2; f) CaCl concentration between 0.5 mM and 5 mM 2 ; d) Sorbitol in concentrations between 1% and 10%; and e) Poloxamer at concentrations between 0.0001% and 0.001%, A pharmaceutical composition containing, Here, the composition is a pharmaceutical composition having a pH between 7.0 and 7.4. (Item 49) a) Recombinant adeno-associated virus (rAAV) particles; b) Approximately 10mM Tris; c) Approximately 130mM NaCl; d) Approximately 2mM KCl; e) Approximately 1mM MgCl 2 ; f) Approximately 1mM CaCl 2 ; d) Approximately 5% sorbitol; and e) Approximately 0.001% poloxamer, Includes, Here, the composition is the pharmaceutical composition described in item 48, having a pH of about 7.2. (Item 50) The poloxamer is poloxamer 188 (Pluronic® F68), as described in any one of items 45 to 49 of the pharmaceutically acceptable composition. (Item 51) The rAAV particles comprise an AAV capsid derived from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, AAVhu37, or a variant thereof, as described in any one of the pharmaceutically acceptable compositions described in any one of the items 45 to 50. (Item 52) The rAAV particles are a pharmaceutical composition according to item 51, comprising an AAV capsid derived from AAV9. (Item 53) A pharmaceutical composition suitable for intrathecal administration, as described in any one of items 1 to 52. (Item 54) The intrathecal administration includes administration into the ventricle, lumbar spine, or cisterna magna, as described in item 53. (Item 55) The rAAV particles comprise an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises a partial or complete coding sequence of CDKL5, or a functional fragment or variant thereof, as described in any one of items 1 to 54 of the pharmaceutically acceptable composition. (Item 56) The pharmaceutical composition according to item 55, wherein the coding sequence of CDKL5 comprises a nucleotide sequence selected from sequence numbers 12-18 and 19, or a nucleotide sequence that is at least 95% identical to any one of sequence numbers 12-19. (Item 57) The pharmaceutical composition according to item 55, wherein the vector genome comprises the nucleotide sequence of SEQ ID NO: 20 or a nucleotide sequence that is at least 95% identical thereto. (Item 58) A method for delivering rAAV to the central nervous system of a subject, the method comprising the step of administering to the subject a pharmaceutical composition described in any one of items 1 to 57. (Item 59) The subject is a mammal, as described in item 58. (Item 60) The method described in item 58 or 59, wherein the administration step includes administration by intrathecal administration. (Item 61) The intrathecal administration described above includes administration into the ventricle, lumbar spine, or cisterna magna, as described in item 60. (Item 62) The intrathecal administration is the method described in item 61, including intracisional administration. [Brief explanation of the drawing]
[0037] The present invention can be better understood by referring to the following drawings.
[0038] [Figure 1] Figure 1 is a bar graph showing the calculated number of genomic copies (GC) per μg of DNA in various brain regions (frontal cortex ("Ctx"), caudal cortex, cerebellum, and brainstem) from brain tissue administered with the rAAV formulations disclosed herein, as further described in Example 2.
[0039] [Figure 2A-D] Figures 2A–2D show representative images of tissue sections with staining corresponding to RNA expression of the vector genome (as detected by BaseScope®) in mice administered with the rAAV formulations disclosed herein, as further described in Example 2. Figures 2A, 2B, 2C, and 2D show images from mouse tissue sections in groups 3, 4, 5, and 6, respectively (see Example 2).
[0040] [Figure 2E-H] Figures 2E-2H are pie charts showing corresponding results from the quantification of BaseScope signals indicating transduction efficiency in the cortex of mice administered with the rAAV formulations disclosed herein, as further described in Example 2.
[0041] [Figure 3]Figure 3 is a bar graph showing the tissue percentage (in cortical tissue) in mice administered with the rAAV formulation disclosed herein, as further described in Example 2.
[0042] [Figure 4A-D] Figures 4A–4D show representative images of tissue sections with staining (detectable by RNAScope®) corresponding to CDKL5 RNA expression in mice administered with the rAAV (in this case, AAV9-SYN-CDKL5) formulation disclosed herein, as further described in Example 2. Figures 4A, 4B, 4C, and 4D show results from mice in groups 3, 4, 5, and 6, respectively (see Example 2).
[0043] [Figure 5] Figure 5 shows stained Western blots for CDKL5 protein expression in caudal cortical tissue from mice administered with the rAAV formulation disclosed herein (in this case, AAV9-SYN-CDKL5), as further described in Example 2. Staining for GADPH protein expression is shown as a loading control. [Modes for carrying out the invention]
[0044] Detailed description of a specific embodiment of the present invention Unless otherwise noted, technical terms are used according to their conventional usage. Definitions of terms common in molecular biology can be found in Benjamin Lewin, Genes V, published by Oxford University Press 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
[0045] To facilitate the consideration of various embodiments of this disclosure, the following explanations of specific terms are provided:
[0046] About: When the term “about” is used before a quantitative value, the present invention also includes that specific quantitative value itself, unless otherwise specifically stated. As used herein, the term “about” means a variation of ±10% from the nominal value, unless otherwise indicated or inferred.
[0047] Adeno-associated virus (AAV): A small, replication-deficient, non-enveloped virus that infects humans and some other primate species. AAV is not known to cause disease and elicits a very mild immune response. Gene therapy vectors utilizing AAV can infect both dividing and resting cells and can persist in an extrachromosomal state without being integrated into the host cell's genome. These characteristics make AAV an attractive viral vector for gene therapy. Currently, there are 13 recognized AAV serotypes (AAV1-13).
[0048] Administering / Delivering: Providing or giving a drug (e.g., a therapeutic agent (e.g., recombinant AAV)) to a subject by any effective route. Exemplary routes of administration include, but are not limited to, injection (e.g., subcutaneous, intramuscular, intradermal, intraperitoneal, intrathecal, intraventricular, or intravenous), oral, intratubal, sublingual, rectal, percutaneous, intranasal, vaginal, and inhalation routes.
[0049] ~between: Unless otherwise noted, when the term "between" is used to refer to a numerical implication, the range includes a specific endpoint. For example, the range "between 1mM and 10mM" includes 1mM, 10mM, and values greater than 1mM but less than 10mM.
[0050] Block copolymer: A "block copolymer" is a polymer composed of blocks of different polymerized monomers. A "diblock copolymer" has two different blocks, while a "triblock copolymer" has three different blocks.
[0051] Code Sequence: A "code sequence" means a nucleotide sequence that codes for a polypeptide in vitro or in vivo when operably ligated to an appropriate regulatory sequence. A code sequence may or may not include prescriptive and postscript sequences (e.g., 5' untranslated (5'UTR) and 3' untranslated (3'UTR) sequences, as well as intervening sequences (introns) between individual coding segments (exons)).
[0052] Codon-Optimized: A "codon-optimized" nucleic acid refers to a nucleic acid sequence in which the codons have been modified to be optimal for expression in a particular system (e.g., a particular species or group of species). For example, a nucleic acid sequence may be optimized for expression in mammalian cells or a particular mammalian species (e.g., human cells). Codon optimization does not alter the amino acid sequence of the protein it encodes.
[0053] Enhancer: A nucleic acid sequence that increases the transcription rate by increasing the activity of the promoter.
[0054] Intrathecal: As used herein, “intrathecal” administration means administration into the intrathecal space that contains cerebrospinal fluid. Examples of intrathecal administration include administration via injection into the spinal cord (e.g., lumbar intrathecal space), into the ventricles (e.g., intraventricular cavity (ICV)), or into the subarachnoid space (e.g., into the cisterna magna (ICM)).
[0055] Introns: Extended portions of DNA within a gene that do not contain protein coding information. Introns are removed before the translation of messenger RNA.
[0056] Inverted end repeats (ITRs): Symmetrical nucleic acid sequences in the adeno-associated virus genome required for efficient replication. ITR sequences are located at each end of the AAV DNA genome. ITRs act as the origin of replication for viral DNA synthesis and are state-of-the-art cis components for generating AAV integration vectors.
[0057] Isolated: An “isolated” biological component (e.g., nucleic acid molecule, protein, virus, or cell) is substantially separated or purified from the cells or tissues of an organism in which it naturally occurs, or from other biological components in the organism itself (e.g., other chromosomes and extrachromosomal DNA and RNA, proteins, and cells). “Isolated” nucleic acid molecules and proteins include those purified by standard purification methods. The above terms also include nucleic acid molecules and proteins prepared by recombinant expression in host cells, as well as chemically synthesized nucleic acid molecules and proteins.
[0058] Operablely linked: A first nucleic acid sequence is operably linked to a second nucleic acid sequence if the first nucleic acid sequence is positioned in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of that coding sequence. Generally, operably linked DNA sequences are contiguous and, if two protein-coding regions need to be joined, they are in the same reading frame.
[0059] Polyhydric alcohol: A polyhydric alcohol is an organic compound that has more than one hydroxyl (-OH) group (examples include dihydric alcohols (which contain two hydroxyl groups) and alcohols that have more than two hydroxyl groups).
[0060] Promoter: A region of DNA that directs / initiates the transcription of a nucleic acid (e.g., a gene). A promoter contains the necessary nucleic acid sequence near the transcription start site. Many promoter sequences are known to those skilled in the art, and furthermore, combinations of different promoter sequences are possible in artificial nucleic acid molecules. As used herein, a gene-specific endogenous promoter means a natural promoter element that regulates the expression of an endogenous gene of interest.
[0061] Purified: The term “purified” does not require absolute purity; rather, it is intended as a relative term. Therefore, for example, a purified peptide, protein, virus, or other active compound is one that has been completely or partially isolated from the naturally associated proteins and other impurities. In certain embodiments, the term “substantially purified” refers to a peptide, protein, virus, or other active compound that has been isolated from cells, cell culture media, or other crude preparations and subjected to fractionation to remove various components of the original preparation (e.g., proteins, cell debris, and other components).
[0062] Recombinant: Recombinant nucleic acid molecules have sequences that do not exist in nature, or sequences that are created by artificially combining two differently separated sequence segments. This artificial combination can be achieved by chemical synthesis or by artificial manipulation of isolated segments of nucleic acid molecules (e.g., by genetic engineering techniques).
[0063] Recombinant AAVs (rAAVs) are described, for example, in Wang et al., "Adeno-associated virus vector as a platform for gene therapy delivery," Nat Rev Drug Discov. 2019 May;18(5):358-378, and Samulski et al., "AAV-Mediated gene therapy for Research and Therapeutic Purposes," Annu Rev Virol. 2014 Nov;1(1):427-51. In this disclosure, rAAVs are used interchangeably with "rAAV particles."
[0064] Sequence Identity: The identity or similarity between two or more nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity or similarity between those sequences. Sequence identity can be measured in terms of percentage identity; a higher percentage indicates more identical sequences. Sequence similarity can be measured in terms of percentage similarity (conservative amino acid substitutions are considered); a higher percentage indicates more similar sequences. Homologs or orthologues of nucleic acid or amino acid sequences, when aligned using standard methods, exhibit a relatively high degree of sequence identity / similarity. This homology is more pronounced when the orthologue protein or cDNA originates from more closely related species (e.g., human and mouse sequences) compared to more distantly related species (e.g., human and C. elegans sequences).
[0065] Alignment methods for sequences used for comparison are well-known in this field. Various programs and alignment algorithms are described below: Smith & Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988; Huang et al., Computer Appls. in the Biosciences 8, 155-65, 1992; and Pearson et al., Meth. Mol. Rio. 24:307-31, 1994. Altschul et al., J. Mol. Biol. 215:403-10, 1990, present detailed considerations for sequence alignment methods and homology calculations.
[0066] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI), and on the internet for use with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. Further information can be found on the NCBI website.
[0067] Serotype: A group of closely related microorganisms (e.g., viruses) distinguished by a characteristic set of antigens.
[0068] A stuffer sequence is a sequence of nucleotides contained within a larger nucleic acid molecule (e.g., a vector) that is typically used to create a desired gap between two nucleic acid features (e.g., between a promoter and a coding sequence) or to extend a nucleic acid molecule so that it reaches a desired length. Stuffer sequences do not contain protein coding information and may be unrelated to other nucleic acid sequences within the larger nucleic acid molecule (unknown / synthetically derived and / or unrelated).
[0069] Subject: A living, multicellular, vertebrate organism (a category including humans and non-human mammals). In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In one embodiment, the human subject is an adult subject, i.e., a human subject over 18 years of age. In one embodiment, the human subject is a pediatric subject, i.e., a human subject between 0 and 18 years of age (inclusive). In some embodiments, the subject (e.g., a human subject) is administered a corticosteroid. In some embodiments, the subject (e.g., a human subject) is administered an IgG-degrading protease. In some embodiments, the subject (e.g., a human subject) is administered a corticosteroid and also an IgG-degrading protease.
[0070] Synthetic: Produced in a laboratory by artificial means. For example, synthetic nucleic acids can be chemically synthesized in a laboratory.
[0071] Untranslated region (UTR): Typical mRNAs have the following locations upstream and downstream of the coding sequence: These regions include the 5' untranslated region (5' UTR) and the 3' untranslated region (3' UTR), respectively (see Mignone F. et al., (2002) Genome Biol 3:REVIEWS0004).
[0072] Therapeutic dose: The amount of a particular drug or therapeutic agent (e.g., recombinant AAV) sufficient to achieve the desired effect in a subject or cell being treated with the drug. The effective dose of the drug depends on several factors, including, but not limited to, the subject or cell being treated and the mode of administration of the therapeutic composition.
[0073] To treat, ameliorate, or prevent a disease: “To treat” refers to a therapeutic intervention that improves the signs or symptoms of a disease or pathological condition after they have begun to appear. “To improve” refers to a reduction in the number or severity of the signs or symptoms of the disease. “To prevent” a disease refers to preventing the complete development of the disease.
[0074] Vector: A vector is a nucleic acid molecule that enables the insertion of foreign nucleic acids without disrupting the vector's ability to replicate and / or be incorporated in a host cell. A vector may contain a nucleic acid sequence (e.g., an origin of replication) that enables replication in a host cell. A vector may also contain one or more selective marker genes and other genetic elements. An expression vector is a vector that contains regulatory sequences necessary to enable transcription and translation of the inserted gene. In some embodiments herein, the vector is an AAV vector. The term “vector” may also be used in a general sense to mean a factor that carries genetic information or genetic material, for example, to introduce such genetic material into a cell or organism. Those skilled in the art will readily understand the general use of the term “vector” as a factor that carries genetic information or genetic material, as well as the more specific use of the term “vector” referring to plasmids or vector genomes within rAAV particles.
[0075] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure belongs. The singular forms “a,” “an,” and “the” include references to the plural unless the context otherwise clearly indicates. “A or B” means A, or B, or A and B. It should be further understood that all base sizes or amino acid sizes and all molecular weight or molecular mass values given with respect to nucleic acids or polypeptides are approximations and are provided for illustrative purposes only. Although similar or equivalent methods and materials may be used in the practice or testing of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated herein by reference in their entirety. In case of any conflict, this specification (including the definition of terms) shall prevail, and furthermore, the materials, methods, and examples described herein are intended to be illustrative and not limiting.
[0076] I. Pharmaceutical Compositions In many embodiments, the composition provided exists in liquid form as a liquid containing, for example, various components as described herein.
[0077] Buffer and pH The compositions provided generally include a buffer / carrier suitable for injection in human subjects. The buffer / carrier should contain components that prevent rAAV from adhering to the injection tube but do not interfere with in vivo rAAV binding activity. Various pH buffers may be suitable for use with the compositions of this disclosure.
[0078] Non-limiting examples of suitable buffering agents include, for example, phosphates and Tris (tris(hydroxymethyl)aminomethane). For example, in some embodiments, the composition contains a phosphate, for example, present in the composition at concentrations between 5 mM and 30 mM phosphate. In some embodiments, the phosphate is present at concentrations between 5 mM and 29 mM, between 5 mM and 28 mM, between 5 mM and 27 mM, between 5 mM and 26 mM, between 5 mM and 25 mM, between 5 mM and 24 mM, between 5 mM and 23 mM, between 5 mM and 22 mM, between 5 mM and 21 mM, between 5 mM and 20 mM, between 5 mM and 19 mM, and between 5 mM and 18 mM. The phosphate is present in the above composition at concentrations between 5 mM and 17 mM, between 5 mM and 16 mM, between 5 mM and 15 mM, between 5 mM and 14 mM, between 5 mM and 13 mM, between 5 mM and 12 mM, between 5 mM and 11 mM, between 5 mM and 10 mM, between 5 mM and 9 mM, between 5 mM and 8 mM, between 5 mM and 7 mM, or between 5 mM and 6 mM. In some embodiments, the phosphate is between 6 mM and 30 mM, 7 mM and 30 mM, 8 mM and 30 mM, 9 mM and 30 mM, 10 mM and 30 mM, 11 mM and 30 mM, 12 mM and 30 mM, 13 mM and 30 mM, 14 mM and 30 mM, 15 mM and 30 mM, 16 mM and 30 mM, and 17 mM and 30 mM. The phosphate is present in the composition at concentrations between 18 mM and 30 mM, between 19 mM and 30 mM, between 20 mM and 30 mM, between 21 mM and 30 mM, between 22 mM and 30 mM, between 23 mM and 30 mM, between 24 mM and 30 mM, between 25 mM and 30 mM, between 26 mM and 30 mM, between 27 mM and 30 mM, between 28 mM and 30 mM, or between 29 mM and 30 mM. In some embodiments, the phosphate is present in the composition at a concentration of at least 5 mM, for example, about 10 mM, about 15 mM, or about 20 mM. In some embodiments, the phosphate is present in the composition at a concentration of about 10 mM.
[0079] In some embodiments, Tris is present in the composition at concentrations between 5 mM and 30 mM, for example. In some embodiments, Tris is present at concentrations between 5 mM and 29 mM, between 5 mM and 28 mM, between 5 mM and 27 mM, between 5 mM and 26 mM, between 5 mM and 25 mM, between 5 mM and 24 mM, between 5 mM and 23 mM, between 5 mM and 22 mM, between 5 mM and 21 mM, between 5 mM and 20 mM, between 5 mM and 19 mM, and between 5 mM and 18 mM. It is present in the above composition at concentrations between 5 mM and 17 mM, between 5 mM and 16 mM, between 5 mM and 15 mM, between 5 mM and 14 mM, between 5 mM and 13 mM, between 5 mM and 12 mM, between 5 mM and 11 mM, between 5 mM and 10 mM, between 5 mM and 9 mM, between 5 mM and 8 mM, between 5 mM and 7 mM, or between 5 mM and 6 mM. In some embodiments, Tris is between 6mM and 30mM, 7mM and 30mM, 8mM and 30mM, 9mM and 30mM, 10mM and 30mM, 11mM and 30mM, 12mM and 30mM, 13mM and 30mM, 14mM and 30mM, 15mM and 30mM, 16mM and 30mM, 17mM and 30mM, and 18mM. Tris is present in the composition at concentrations between M and 30mM, between 19mM and 30mM, between 20mM and 30mM, between 21mM and 30mM, between 22mM and 30mM, between 23mM and 30mM, between 24mM and 30mM, between 25mM and 30mM, between 26mM and 30mM, between 27mM and 30mM, between 28mM and 30mM, or between 29mM and 30mM. In some embodiments, Tris is present in the composition at a concentration of at least 5mM, for example, about 10mM, about 15mM, or about 20mM. In some embodiments, Tris is present in the composition at a concentration of about 10mM.
[0080] The pH of the provided composition is generally between 6.5 and 8.5, for example, between 7.0 and 8.5, between 7.5 and 8, or between 7.0 and 7.4. In some embodiments, the composition has a pH of about 7.2.
[0081] polyhydric alcohols Suitable polyhydric alcohols, though not limited to specific examples, include polyethylene glycol, propylene glycol, and sugar alcohols.
[0082] In certain embodiments, the polyhydric alcohol is a sugar alcohol. In some embodiments, the polyhydric alcohol is a sugar alcohol selected from the group consisting of erythritol, glycerol, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol. In some embodiments, the sugar alcohol is sorbitol. In some embodiments, the polyhydric alcohol is a sugar alcohol in the form of mono-(erythritol, xylitol, sorbitol, mannitol), di-(lactitol, isomalt, maltitol), or its hydrogenated form in polysaccharide form.
[0083] In some embodiments, the polyhydric alcohol is present in the formulation in an amount ranging from 0.5% to 20% (unless otherwise noted, percentages of polyhydric alcohol in liquid compositions throughout this disclosure refer to weight / volume percentages; 1 g / 100 mL is equal to 1% (w / v)). In some embodiments, the polyhydric alcohol is present in the formulation in the range of 0.5% to 19%, 0.5% to 18%, 0.5% to 17%, 0.5% to 16%, 0.5% to 15%, 0.5% to 14%, 0.5% to 13%, 0.5% to 12%, 0.5% to 11%, 0.5% to 10%, 0.5% to 9%, 0.5% to 8%, 0.5% to 7%, 0.5% to 6%, 0.5% to 5%, 0.5% to 4%, 0.5% to 3%, 0.5% to 2%, 0.5% to 1%, 0.5% to 0.9%, 0.5% to 0.8%, 0.5% to 0.7%, or 0.5% to 0.6%. In some embodiments, the polyhydric alcohol is present in the formulation in the range of 0.6%~20%, 0.7%~20%, 0.8%~20%, 0.9%~20%, 1%~20%, 2%~20%, 3%~20%, 4%~20%, 5%~20%, 6%~20%, 7%~20%, 8%~20%, 9%~20%, 10%~20%, 11%~20%, 12%~20%, 13%~20%, 14%~20%, 15%~20%, 16%~20%, 17%~20%, 18%~20%, or 19%~20%. In some embodiments, the polyhydric alcohol is present in the formulation in the range of 1%~10%. In some embodiments, polyhydric alcohols are present in the formulation at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some embodiments, polyhydric alcohols are present in the formulation at about 5% or about 10%.
[0084] In some exemplary embodiments, the composition comprises sorbitol. In some embodiments, sorbitol is present in the formulation in an amount ranging from 0.5% to 20%. In some embodiments, sorbitol is present in the above formulation at concentrations of 0.5% to 19%, 0.5% to 18%, 0.5% to 17%, 0.5% to 16%, 0.5% to 15%, 0.5% to 14%, 0.5% to 13%, 0.5% to 12%, 0.5% to 11%, 0.5% to 10%, 0.5% to 9%, 0.5% to 8%, 0.5% to 7%, 0.5% to 6%, 0.5% to 5%, 0.5% to 4%, 0.5% to 3%, 0.5% to 2%, 0.5% to 1%, 0.5% to 0.9%, 0.5% to 0.8%, 0.5% to 0.7%, or 0.5% to 0.6%. In some embodiments, sorbitol is present in the formulation in the range of 0.6%~20%, 0.7%~20%, 0.8%~20%, 0.9%~20%, 1%~20%, 2%~20%, 3%~20%, 4%~20%, 5%~20%, 6%~20%, 7%~20%, 8%~20%, 9%~20%, 10%~20%, 11%~20%, 12%~20%, 13%~20%, 14%~20%, 15%~20%, 16%~20%, 17%~20%, 18%~20%, or 19%~20%. In some embodiments, sorbitol is present in the formulation in the range of 1%~10%. In some embodiments, sorbitol is present in the formulation at about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some embodiments, sorbitol is present in the formulation at about 5% or about 10%.
[0085] Triblock copolymer surfactant Non-limiting examples of suitable triblock copolymer surfactants include nonionic triblock copolymer surfactants (e.g., copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) (e.g., poloxamers)). Poloxamers are triblock copolymers composed of two hydrophilic chains of poly(ethylene oxide) (PEO) adjacent to a central hydrophobic chain of poly(propylene oxide) (PPO). Poloxamers typically exhibit a molecular weight range of approximately 1,000 to 15,000.
[0086] In some embodiments, the triblock copolymer surfactant is a poloxamer, for example, poloxamer 188 (Pluronic F68®).
[0087] In some embodiments, the triblock copolymer surfactant (e.g., poloxamer) is present in the composition at a concentration of at least 0.0001%, at least 0.0005%, or at least 0.001% (unless otherwise noted, the percentage of triblock copolymer surfactant (e.g., poloxamer) in a liquid composition throughout this disclosure refers to a weight / volume percentage; 1 g / 100 mL is equal to 1% (w / v)). In some embodiments, the triblock copolymer surfactant (e.g., poloxamer) is present in the composition at a concentration of 0.0001% to about 0.001%. In some embodiments, the above triblock copolymer surfactant (e.g., poloxamer) is present in concentrations between 0.0002% and 0.001%, between 0.0003% and 0.001%, between 0.0004% and 0.001%, between 0.0005% and 0.001%, between 0.0006% and 0.001%, between 0.0007% and 0.001%, between 0.0008% and 0.001%, and 0.000 It is present in the above composition at concentrations between 9% and 0.001%, between 0.0001% and 0.0009%, between 0.0001% and 0.0008%, between 0.0001% and 0.0007%, between 0.0001% and 0.0006%, between 0.0001% and 0.0005%, between 0.0001% and 0.0004%, between 0.0001% and 0.0003%, or between 0.0001% and 0.0002%.
[0088] salt The provided composition may include physiologically compatible salts or mixtures of salts. In some embodiments, any included salts are adjusted to an ionic strength equivalent to about 100 mM sodium chloride (NaCl) to about 250 mM sodium chloride, or physiologically compatible salts are adjusted to an equivalent ionic concentration.
[0089] For example, the provided composition may contain one or more salts, e.g., one or more monovalent salts and / or one or more divalent salts. For example, the provided composition may contain monovalent salts selected from the group consisting of NaCl, KCl, or combinations thereof. For example, in some embodiments, NaCl may be in concentrations between 100mM and 250mM, between 100mM and 240mM, between 100mM and 230mM, between 100mM and 220mM, between 100mM and 210mM, between 100mM and 200mM, between 100mM and 190mM, between 100mM and 180mM, between 100mM and 170mM, between 100mM and 160mM, between 100mM and 150mM, between 100mM and 140mM, 1 It is present in the above composition at concentrations between 00mM and 130mM, between 100mM and 120mM, between 100mM and 110mM, between 90mM and 200mM, between 110mM and 200mM, between 120mM and 200mM, between 130mM and 200mM, between 140mM and 200mM, between 150mM and 200mM, between 160mM and 200mM, between 170mM and 200mM, between 180mM and 200mM, or between 190mM and 200mM.
[0090] In some embodiments, NaCl is present in the composition at a concentration of about 130 mM or about 135 mM.
[0091] In some embodiments, KCl is present in the above composition at concentrations between 0.5 mM and 5 mM, between 0.6 mM and 5 mM, between 0.7 mM and 5 mM, between 0.8 mM and 5 mM, between 0.9 mM and 5 mM, between 1 mM and 5 mM, between 1.5 mM and 5 mM, between 2 mM and 5 mM, between 2.5 mM and 5 mM, between 3 mM and 5 mM, between 3.5 mM and 5 mM, between 4 mM and 5 mM, between 4.5 mM and 5 mM, between 0.5 mM and 4.5 mM, between 0.5 mM and 4 mM, between 0.5 mM and 3.5 mM, between 0.5 mM and 3 mM, between 0.5 mM and 2.5 mM, between 0.5 mM and 2 mM, or between 0.5 mM and 1 mM.
[0092] In some embodiments, KCl is present in the composition at a concentration of about 2 mM.
[0093] Non-specific examples of suitable divalent salts include MgCl2, CaCl2, or combinations thereof. For example, in some embodiments, MgCl2 is present in the above composition at concentrations between 0.5mM and 5mM, between 0.6mM and 5mM, between 0.7mM and 5mM, between 0.8mM and 5mM, between 0.9mM and 5mM, between 1mM and 5mM, between 1.5mM and 5mM, between 2mM and 5mM, between 2.5mM and 5mM, between 3mM and 5mM, between 3.5mM and 5mM, between 4mM and 5mM, between 4.5mM and 5mM, between 0.5mM and 4.5mM, between 0.5mM and 4mM, between 0.5mM and 3.5mM, between 0.5mM and 3mM, between 0.5mM and 2.5mM, between 0.5mM and 2mM, or between 0.5mM and 1mM.
[0094] In some embodiments, MgCl2 is present in the composition at a concentration of about 1 mM.
[0095] In some embodiments, CaCl2 is present in the above composition at concentrations between 0.5 mM and 5 mM, between 0.6 mM and 5 mM, between 0.7 mM and 5 mM, between 0.8 mM and 5 mM, between 0.9 mM and 5 mM, between 1 mM and 5 mM, between 1.5 mM and 5 mM, between 2 mM and 5 mM, between 2.5 mM and 5 mM, between 3 mM and 5 mM, between 3.5 mM and 5 mM, between 4 mM and 5 mM, or between 4.5 mM and 5 mM, between 0.5 mM and 4.5 mM, between 0.5 mM and 4 mM, between 0.5 mM and 3.5 mM, between 0.5 mM and 3 mM, between 0.5 mM and 2.5 mM, between 0.5 mM and 2 mM, or between 0.5 mM and 1 mM.
[0096] In some embodiments, CaCl2 is present in the composition at a concentration of about 1 mM.
[0097] Recombinant AAV (rAAV): This disclosure describes, for example, compositions for delivering rAAV to the central nervous system of a subject, for example, for gene therapy, and methods of using them.
[0098] AAV belongs to the family Parvoviridae and the genus Dependovirus. AAV is a small, non-enveloped virus that packages a linear, single-stranded DNA genome. Both the sense and antisense strands of AAV DNA are packaged into the AAV capsid at equal frequency.
[0099] The AAV genome described above is characterized by two inverted end repeat sequences (ITRs) adjacent to two open reading frames (ORFs). In the AAV2 genome described above, for example, the first 125 nucleotides of the ITR are a palindrome, which folds itself to maximize base pairing, forming a T-shaped hairpin structure. The other 20 bases of the ITR (called the D sequence) remain unpaired. The ITR is a cis-active sequence important for AAV DNA replication; it is the origin of replication and acts as a primer for second-strand synthesis by DNA polymerase. The double-stranded DNA formed during this synthesis (called the replication morphology monomer) is used for a second self-sensitized replication, forming a replication morphology dimer. These double-stranded intermediates are processed via a strand substitution mechanism, yielding single-stranded DNA used for packaging and double-stranded DNA used for transcription. The rep-binding element and end separation site (TRS) are located within the ITR. These features are used by the viral regulatory protein Rep during AAV replication to process the double-stranded intermediate. In addition to their roles in AAV replication, the above ITRs are also essential for AAV genome packaging, transcription, negative regulation under unacceptable conditions, and site-specific integration (Days and Berns, Clin Microbiol Rev 21(4):583-593, 2008).
[0100] The left-hand ORF of AAV contains the Rep genes, which encode four proteins: Rep78, Rep68, Rep52, and Rep40. The right-hand ORF contains the Cap gene, which produces three viral capsid proteins (VP1, VP2, and VP3). The AAV capsid contains 60 viral capsid proteins arranged in icosahedral symmetry. VP1, VP2, and VP3 are present in a 1:1:10 molar ratio (Daya and Berns, Clin Microbiol Rev 21(4):583-593, 2008).
[0101] AAV is currently one of the most frequently used viruses for gene therapy. Although AAV infects humans and several other primate species, it is not known to cause disease and elicits a very mild immune response. Gene therapy vectors utilizing AAV can infect both dividing and resting cells and persist in an extrachromosomal state without being integrated into the host cell genome. Due to the advantageous characteristics of AAV, this disclosure intends to use AAV for recombinant nucleic acid molecules and methods disclosed herein.
[0102] AAV possesses several desirable characteristics of gene therapy vectors, including the ability to bind to target cells, enter them, access the nucleus, be expressed in the nucleus over an extended period, and exhibit low toxicity. However, due to the small size of the AAV genome, the size of heterologous DNA that can be incorporated is limited. To minimize this issue, AAV vectors that do not encode Rep and integration efficiency elements (IEE) have been constructed. The ITRs described above are retained because they are the cis signals required for packaging (Daya and Berns, Clin Microbiol Rev, 21(4):583-593, 2008). Methods for generating rAAV suitable for gene therapy are well known in the art (see, for example, U.S. Patent Application Publication Nos. 2012 / 0100606; 2012 / 0135515; 2011 / 0229971; and 2013 / 0072548; as well as Ghosh et al., Gene Ther 13(4):321-329, 2006) and can be utilized with the recombinant nucleic acid molecules and methods disclosed herein.
[0103] In some aspects, the present disclosure provides the use of the rAAV disclosed herein for the treatment of a disorder (e.g., a disorder affecting the central nervous system), wherein the rAAV comprises an AAV capsid and a vector genome packaged within the AAV capsid. In some embodiments, the rAAV comprises a packaged genome that includes, as operably linked components in 5' to 3' order: a 5'-ITR, a promoter sequence, a heterologous gene, or a partial or complete coding sequence for a functional fragment or functional variant thereof, and a 3'-ITR.
[0104] In some embodiments, the recombinant adeno-associated virus (rAAV) particles are at 1×10 10 ~4×10 14 GC / mL, 1×10 10 ~3×10 14 GC / mL, 1×10 10 ~2×10 14 GC / mL, 1×1010 ~1 × 10 14 During GC / mL, 1 × 10 11 ~1 × 10 13 During GC / mL, 1 × 10 12~ 6×10 12 Between GC / mL, or 1 × 10 12 ~4×10 12 It is present in the above composition at a concentration between GC / mL.
[0105] In some embodiments, the rAAV comprises an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises (a) a promoter sequence; and (b) a heterogene (e.g., a heterogene encoding a therapeutic gene product) or a partial or complete coding sequence of its functional fragment or functional variant.
[0106] In some embodiments, the packaged vector genome may further comprise a 5'-ITR sequence, enhancers, introns, consensus Kozak sequences, polyadenylation signals, and / or 3'-ITR sequences, as described herein. In some embodiments, the recombinant vector may further comprise one or more stuffer nucleic acid sequences. In one embodiment, the stuffer nucleic acid sequence is located between an intron and the partial or complete coding sequence of the heterologous gene.
[0107] In various embodiments described herein, the rAAV comprises an AAV capsid. The AAV capsid may be derived from any one of AAVs of serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, rh10, or hu37 (i.e., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, AAVhu37), as well as from more than 100 variants isolated from human and non-human primate tissues. See, for example, Choi et al., 2005, Curr Gene Ther. 5: 299-310, 2005 and Gao et al., 2005, Curr Gene Ther. 5: 285-297.
[0108] In addition to the aforementioned capsids, variant AAV capsids that have been engineered to possess one or more beneficial therapeutic properties (e.g., improved targeting of selected tissues, increased ability to evade immune responses, reduced stimulation of neutralizing antibodies, etc.) are included within the scope of the present invention. Non-limiting examples of such manipulated variant capsids include U.S. Patent Nos. 9,506,083, 9,585,971, 9,587,282, 9,611,302, 9,725,485, 9,856,539, 9,909,142, 9,920,097, 10,011,640, 10,081,659, 10,179,176, 10,202,657, 10,214,566, and the same. This information is provided in publications No. 10,214,785, No. 10,266,845, No. 10,294,281, No. 10,301,648, No. 10,385,320, and No. 10,392,632, as well as in PCT publication numbers WO / 2017 / 165859, WO / 2018 / 022905, WO / 2018 / 156654, WO / 2018 / 222503, and WO / 2018 / 226602 (these disclosures are incorporated herein by reference).
[0109] In certain exemplary embodiments, the rAAV administered according to the present invention comprises an AAV9 capsid. The AAV9 capsid is a self-assembled AAV capsid composed of multiple AAV9 vp proteins. The AAV9 vp proteins are typically expressed as alternative splice variants encoded by the nucleic acid sequence of SEQ ID NO: 11, which encodes the vp1 amine acid sequence of SEQ ID NO: 1 (GenBank Accession: AAS99264), or by a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical thereto. These splice variants result in proteins of different lengths of SEQ ID NO: 1. As used herein, AAV9 variants include, for example, those described in WO / 2016 / 049230, U.S. Patent No. 8,927,514, U.S. Patent Publication No. 2015 / 0344911, and U.S. Patent No. 8,734,809.
[0110] As described herein, the rAAV administered according to the present invention may, in some embodiments, comprise the AAV9 capsid. However, in other embodiments, a different AAV capsid may be selected. Tissue specificity may be determined by the capsid type. An AAV serotype that transduces a suitable target (e.g., liver, muscle, lung, or CNS) may be selected as the source of the capsid for an AAV virus vector (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrh10, AAVrh64Rl, AAVrh64R2, AAVrh8). See, for example, U.S. Patent Publication 2007 / 0036760; U.S. Patent Publication 2009 / 0197338; and EP1310571. See also WO 2003 / 042397 (AAV7 and other Simian AAVs), U.S. Patent No. 7,282199 and U.S. Patent No. 7,790449 (AAV8). Furthermore, AAVs not yet discovered, or recombinant AAVs based thereon, may be used as sources for AAV capsids. These documents also describe other AAVs that may be selected to generate AAVs and are incorporated by reference. In some embodiments, AAV capsids for use in viral vectors may be generated by mutagenesis (i.e., insertion, deletion, or substitution) of one of the aforementioned AAV capsids or their coding nucleic acids. In some embodiments, the AAV capsid is a chimera containing domains derived from two, three, four or more of the aforementioned AAV capsid proteins. In some embodiments, the AAV capsid is a mosaic of Vp1, Vp2, and Vp3 monomers derived from two or three different AAVs or recombinant AAVs. In some embodiments, the rAAV composition contains more than one of the aforementioned capsids.
[0111] In some embodiments, the rAAV comprises an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises a partial or complete coding sequence of CDKL5, or functional fragments or variants thereof.
[0112] In some embodiments, the coding sequence of CDKL5 includes a nucleotide sequence selected from the group consisting of SEQ ID NOs. 12-18 and 19, or a nucleotide sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identical to any of SEQ ID NOs. 12-19.
[0113] In exemplary embodiments, the rAAV comprises an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises the nucleotide sequence of SEQ ID NO: 20, or a nucleotide sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or at least 99.9% identical thereto. In some such embodiments, the AAV capsid is an AAV9 capsid.
[0114] Inverted terminal repeat (ITR): In some embodiments, rAAV comprises a packaged vector genome containing an AAV ITR sequence, which functions as both a vector DNA replication origin and a vector genome packaging signal when AAV and adenovirus helper functions are provided in trans. Furthermore, the ITR acts as a target for single-stranded endonucleatic nicking by a large Rep protein, separating individual genomes from replication intermediates.
[0115] In some embodiments, the 5'-ITR sequence is derived from AAV2. In some embodiments, the 3'-ITR sequence is derived from AAV2. In some embodiments, the 5'-ITR sequence and the 3'-ITR sequence are derived from AAV2. In some embodiments, the 5'-ITR sequence and / or the 3'-ITR sequence are derived from AAV2 and include or consist of sequence number 2. In other embodiments, the 5'-ITR sequence and / or the 3'-ITR sequence are derived from a non-AAV2 source.
[0116] promoter In various aspects described herein, the rAAV comprises a packaged vector genome containing a promoter sequence that helps drive and regulate the expression of heterologous genes. In exemplary embodiments, the promoter sequence is located between the 5'-ITR sequence and the partial or complete coding sequence of the heterologous gene. In some embodiments, the promoter sequence is located downstream of an enhancer sequence. In some embodiments, the promoter sequence is located upstream of an intron sequence.
[0117] In some embodiments, the promoter is a neuron-specific promoter. In one embodiment, the neuron-specific promoter is selected from the human synapsin 1 (SYN1) promoter, the mouse calcium / calmodulin-dependent protein kinase II (CaMKII) promoter, the rat tubulin αI (Ta1) promoter, the rat neuron-specific enolase (NSE) promoter, the human neuron-specific enolase (ENO2) promoter, the human platelet-derived growth factor β chain (PDGF) promoter, the human BM88 promoter, and the neuronal nicotinic receptor β2 (CHRNB2) promoter.
[0118] In exemplary embodiments, the neuron-specific promoter is the SYN1 promoter (e.g., the human SYN1 promoter). In one embodiment, the SYN1 promoter (e.g., the human SYN1 promoter) is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than%. In exemplary embodiments, the SYN1 promoter (e.g., the human SYN1 promoter) comprises or consists of the SYN1 promoter (e.g., the human SYN1 promoter).
[0119] In some embodiments, the promoter is selected from the chicken β-actin (CBA) promoter, the cytomegalovirus (CMV) early gene promoter, the transthyretin (TTR) promoter, the thyroxine-binding globulin (TBG) promoter, and the α-1 antitrypsin (A1AT) promoter.
[0120] In an exemplary embodiment, the promoter is a CBA promoter. In one embodiment, the CBA promoter includes or consists of SEQ ID NO: 4.
[0121] In some embodiments, the promoter is a gene-specific endogenous promoter. In one embodiment, the promoter comprises a native gene promoter element.
[0122] Other packaged trigenomic elements In addition to promoter and heterologous gene coding sequences, the packaged genome may contain other appropriate transcription start sequences, termination sequences, enhancer sequences, and efficient RNA processing signals. As will be described in more detail below, such sequences include splicing signals and polyadenylation (poly-A) signals, regulatory elements that enhance expression, sequences that stabilize cytoplasmic mRNA, sequences that enhance translation efficiency (i.e., Kozak consensus sequences), and sequences that enhance protein stability.
[0123] In some embodiments, the rAAV comprises a packaged vector genome containing one or more enhancer sequences. In one embodiment, the enhancers are selected from a cytomegalovirus early gene (CMV) enhancer, a transthyretin enhancer (enTTR), a chicken β-actin (CBA) enhancer, an En34 enhancer, and an ApoE enhancer. In an exemplary embodiment, the enhancer is a CMV enhancer (e.g., a CMV early gene enhancer). In one embodiment, the CMV enhancer (e.g., a CMV early gene enhancer) comprises or consists of sequence number 7.
[0124] In some embodiments, the rAAV comprises a packaged vector genome containing one or more intron sequences. In one embodiment, the intron is selected from the SV40 Small T intron, the rabbit hemoglobin subunit β(rHBB) intron, the human β-globin IVS2 intron, the β-globin / IgG chimeric intron, and the hFIX intron. In one exemplary embodiment, the intron is the SV40 Small T intron. In one embodiment, the SV40 Small T intron sequence contains or consists of SEQ ID NO: 8.
[0125] In some embodiments, the rAAV comprises a packaged vector genome that includes a consensus Kozak sequence. In some embodiments, the consensus Kozak sequence is located downstream of the intron sequence. In one embodiment, the consensus Kozak sequence is GCCGCCACC.
[0126] In some embodiments, the rAAV comprises a packaged vector genome that includes a polyadenylation signal sequence. In one embodiment, the polyadenylation signal sequence is selected from a bovine growth hormone (BGH) polyadenylation signal sequence, an SV40 polyadenylation signal sequence, a rabbit β-globin polyadenylation signal sequence, and a gene-specific endogenous polyadenylation signal sequence. In an exemplary embodiment, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence. In one embodiment, the SV40 polyadenylation signal sequence comprises or consists of SEQ ID NO: 5.
[0127] II. Method of delivering rAAV In one aspect, the present disclosure provides a method of delivering rAAV to the central nervous system of a subject, the method comprising the step of administering to the subject a pharmaceutical composition as described herein.
[0128] In an exemplary embodiment, the pharmaceutical composition is administered intrathecally, for example, via intracerebroventricular, lumbar, or intracisternal administration. In some embodiments, the pharmaceutical composition is administered by intracisternal administration.
[0129] For example, in some embodiments, the above pharmaceutical composition is administered using an automated intrathecal injector. For example, injectors that influence CSF dynamics, physiological pulsatile, and volume displacement may be used to deliver rAAV intrathecally. One example of a possible injector for use in the method of the present invention is the Pulsar developed by Alcyone Lifesciences, Inc. TM This is a Smart Intrathecal Delivery Platform.
[0130] The specific dose administered should be a uniform dose for each patient, for example, 1.0 × 10⁶ per patient. 11 ~1.0×10 14 The virus may be a genome copy (GC). Alternatively, the patient's dose may be adjusted to the patient's approximate body weight or surface area. Other factors in determining the appropriate dose may include the disease or condition being treated or prevented, the severity of the disease, the route of administration, and the patient's age, sex, and medical condition. Further refinements to the calculations necessary to determine the appropriate dose for treatment are customarily made by those skilled in the art, particularly in light of the dose information and assays disclosed herein. The dose may also be determined through the use of known assays to determine the dose to be used in conjunction with appropriate dose-response data. The dose for an individual patient may also be adjusted as the progression of the disease is monitored.
[0131] In some embodiments, the above pharmaceutical composition is measured by qPCR or droplet digital PCR (ddPCR), for example, about 1.0 × 10⁻¹⁶. 11 Genome copies / kg Patient body weight (GC / kg) ~ approximately 1 × 10⁻⁶ 14 GC / kg, approx. 5×10 11 Genome copies / kg Patient body weight (GC / kg) ~ approximately 5 × 10 13 GC / kg, or approximately 1 × 10⁻⁶ 12 ~Approx. 1×10 13It is administered in doses of rAAV in GC / kg. In some embodiments, the above rAAV is approximately 1 × 10⁻⁶ 12 ~Approx. 1×10 13 It is administered in doses of genome copies (GC) / kg. In some embodiments, the above rAAV is approximately 1.1 × 10⁻⁶ 11 , about 1.3×10 11 , about 1.6×10 11 , about 1.9×10 11 , about 2×10 11 , about 2.5×10 11 , about 3.0×10 11 , about 3.5×10 11 , about 4.0×10 11 , about 4.5×10 11 , about 5.0×10 11 , about 5.5×10 11 , about 6.0×10 11 , about 6.5×10 11 , about 7.0×10 11 , about 7.5×10 11 , about 8.0×10 11 , about 8.5×10 11 , about 9.0×10 11 , about 9.5×10 11 , about 1.0×10 12 , about 1.5×10 12 , about 2.0×10 12 , about 2.5×10 12 , about 3.0×10 12 , about 3.5×10 12 , about 4.0×10 12 , about 4.5×10 12 , about 5.0×10 12 , about 5.5×10 12 , about 6.0×10 12 , about 6.5×10 12 , about 7.0×10 12 , about 7.5×10 12 , about 8.0×10 12 , about 8.5×10 12 , about 9.0×10 12 , about 9.5×10 12 , about 1.0×10 13 , about 1.5×10 13 , about 2.0×10 13 , about 2.5×10 13, about 3.0×10 13 , about 3.5×10 13 , about 4.0×10 13 , about 4.5×10 13 , about 5.0×10 13 , about 5.5×10 13 , about 6.0×10 13 , about 6.5×10 13 , about 7.0×10 13 , about 7.5×10 13 , about 8.0×10 13 , about 8.5×10 13 , about 9.0×10 13 , about 9.5×10 13 It is administered in doses of genome copies (GC) / kg. The above rAAV may be administered as a single dose or in multiple doses (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) if necessary for the desired therapeutic outcome.
[0132] In some embodiments, a method for delivering rAAV according to the present invention may further include the administration of an IgG-degrading protease before administering the pharmaceutical composition described herein.
[0133] In some embodiments, the delivery method according to the present invention is performed on a subject (e.g., a mammal, e.g., a human) that has been administered an IgG-degrading protease.
[0134] Examples of proteases that may be used in the present invention include, but are not limited to, those described in WO / 2020 / 016318 and / or WO / 2020 / 159970 (e.g., cysteine proteases derived from Streptococcus pyogenes, Streptococcus equi, Mycoplasma canis, Streptococcus agalactiae, Streptococcus pseudoporcinus, or Pseudomonas putida).
[0135] In certain embodiments, the IgG-degrading protease is IdeS (SEQ ID NO: 9) derived from Streptococcus pyogenes, or a protease that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 9. In some embodiments, the protease is an engineered variant of SEQ ID NO: 9. Examples of engineered IdeS proteases are described in WO / 2020 / 016318 and U.S. Patent Publications 20180023070 and 20180037962. In some embodiments, the engineered IdeS variant may have one, two, three, four, five, or more amino acid modifications compared to SEQ ID NO: 9.
[0136] In certain embodiments, the IgG-degrading protease is a protease that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to IdeZ (SEQ ID NO: 10) derived from Streptococcus equi. In some embodiments, the protease is an engineered variant of SEQ ID NO: 10. Examples of engineered IdeZ proteases are described in WO / 2020 / 016318. In some embodiments, the engineered IdeZ variant may have one, two, three, four, five, or more amino acid modifications compared to SEQ ID NO: 10.
[0137] Other proteases that may be used in the present invention include, but are not limited to, the IgdE enzymes derived from Streptococcus suis, Streptococcus porcinus, and Streptococcus equi, as described in WO / 2017 / 134274.
[0138] In some embodiments, the IgG-degrading protease can be encapsulated in or complexed with liposomes, nanoparticles, lipid nanoparticles (LNPs), polymers, microparticles, microcapsules, micelles, or extracellular vesicles.
[0139] corticosteroids In some embodiments, the provided method comprises the step of administering a composition comprising rAAV as disclosed herein to a subject who has previously received a corticosteroid. The compositions disclosed herein may be administered intrathecally, for example, into the ventricles, or via intracisional delivery.
[0140] In various embodiments following this circumstance, the corticosteroid may be selected from prednisolone, prednisone, dexamethasone, hydrocortisone, triamcinolone, methylprednisolone, budesonide, betamethasone, and deflazacort. In an exemplary embodiment, the corticosteroid is prednisolone.
[0141] In various embodiments following this phasing, the corticosteroid is administered to the subject at least about 12 hours before administration of the composition containing rAAV. In another embodiment, the corticosteroid is administered to the subject at least about 24 hours before administration of the composition containing rAAV. In yet another embodiment, the corticosteroid is administered to the subject at least about 2 days before administration of the composition containing rAAV. In yet another embodiment, the corticosteroid is administered to the subject at least about 3, 4, 5, 6, 7 days, or more than 7 days before administration of the composition containing rAAV. In yet another embodiment, the corticosteroid is administered to the subject at least about 7, 14, 21 days, or more than 21 days before administration of the composition containing rAAV. In yet another embodiment, the corticosteroid is administered to the subject at least about one month, at least about two months, or at least about three months before administration of the composition containing rAAV. In some embodiments, the corticosteroid is administered between 12 hours and 4 months before administration of the composition containing rAAV, for example, between 24 hours and 3 months prior.
[0142] In one embodiment, the corticosteroid is administered once before administering the composition containing the rAAV. In another embodiment, the corticosteroid is administered twice before administering the composition containing the rAAV. In yet another embodiment, the corticosteroid is administered three, four, five, or more times before administering the composition containing the rAAV.
[0143] The administration of the above-mentioned corticosteroids to human subjects may be by any route (including, but not limited to, oral, intravenous, intradermal, transdermal, subcutaneous, intramuscular, inhalation (e.g., via aerosol), buccal (e.g., sublingual), topical (i.e., both skin and mucous membrane surfaces (including airway surfaces)), intrathecal, intra-articular, intrapleural, intracerebral, intra-arterial, intraperitoneal, or intranasal administration). In exemplary embodiments, the above-mentioned corticosteroids are administered orally.
[0144] In certain embodiments, the dose of corticosteroids is measured in units of mg / kg of subject body weight. In other embodiments, the dose of corticosteroids is measured in mg per dose administered to the subject. Any measured values of doses and units of administration that can be used with the compositions and methods of the present invention can be converted by means of art standard.
[0145] In certain embodiments, the corticosteroid may be administered in doses of approximately 1 mg to approximately 1000 mg. In some embodiments, the corticosteroid is administered in doses of approximately 3 mg to approximately 300 mg. In some embodiments, the corticosteroid is administered in doses of approximately 5 mg to approximately 150 mg. In some embodiments, the corticosteroid is administered in doses of approximately 10 mg to approximately 100 mg. In some embodiments, the corticosteroid is administered in doses of approximately 15 mg to approximately 80 mg. In some embodiments, the corticosteroid is administered in doses of approximately 20 mg to approximately 60 mg.
[0146] In a particular embodiment, the above corticosteroids are approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, It can be administered in doses of approximately 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg.
[0147] In certain embodiments, the corticosteroid may be administered in a dose of approximately 0.1 mg / kg to approximately 100 mg / kg of subject body weight. In some embodiments, the anti-CD19 antibody is administered in a dose of approximately 0.2 mg / kg to approximately 10 mg / kg. In some embodiments, the anti-CD19 antibody is administered in a dose of approximately 0.5 mg / kg to approximately 5 mg / kg. In some embodiments, the anti-CD19 antibody is administered at doses of approximately 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.1 mg / kg, 1.2 mg / kg, 1.3 mg / kg, 1.4 mg / kg, 1.5 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, or 10 mg / kg of subject body weight.
[0148] In some embodiments, the corticosteroid may be administered for a total of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, or more days prior to administration of the composition comprising rAAV. In some embodiments, the corticosteroid is administered for 1 day to 14 days, for example 1 day to 12 days, or 1 day to 10 days prior to administration of the composition comprising rAAV. For example, in certain exemplary embodiments, the corticosteroid may be administered at 1 mg / kg / day for 5 days prior to administration of the composition comprising rAAV.
[0149] In some embodiments, the corticosteroid may be administered at 1 mg / kg / day for 4 weeks, with the first administration occurring 5 days prior to administration of the composition comprising rAAV. In some embodiments, the corticosteroid may be administered at 1 mg / kg / day for 4 weeks, with the first administration occurring 5 days prior to administration of the composition comprising rAAV, followed by a gradual tapering of the corticosteroid over an additional 4 weeks.
[0150] The methods according to this aspect can be used to treat any CNS disorder for which gene therapy may be appropriate. In some embodiments, the CNS disorder is selected from CDKL5 deficiency disorder (CDD), Angelman syndrome, Batten disease, Krabbe disease, Parkinson's disease, Alzheimer's disease, spinal muscular atrophy (SMA) type I, type II, type III and type IV, X-linked myotubular myopathy, Friedreich's ataxia, Canavan disease, amyotrophic lateral sclerosis (ALS), adrenoleukodystrophy, Huntington's disease, Rett syndrome, and spinocerebellar ataxia.
[0151] Throughout the detailed description, where a composition is described as having, encompassing, or including certain components, or where a process and method is described as having, encompassing, or including certain steps, it is intended that there exist compositions of the present invention that are essentially composed of or consist of such described components, and that there exist processes and methods according to the present invention that are essentially composed of or consist of such described processing steps.
[0152] Wherever an element or component is said to be included in and / or selected from a list of elements or components described in this disclosure, it should be understood that the element or component may be any one of the elements or components described, or it may be selected from a group of two or more of the elements or components described.
[0153] Furthermore, it should be understood that elements and / or features of the compositions or methods described herein, whether express or implied herein, can be combined in various ways without departing from the spirit and scope of the invention. For example, where a particular compound is referred to, that compound can be used in various embodiments of the compositions of the invention and / or in the methods of the invention unless otherwise understood from the context. In other words, while embodiments in this disclosure are described and shown in a manner that enables a clear and concise disclosure to be written and depicted, it is intended and recognized that embodiments may be combined in various ways or separated without being destined from the teachings and the invention. For example, it is recognized that all features described and shown herein may be applicable to all aspects of the invention described and shown herein.
[0154] It should be understood that the expression “at least one of” includes, unless otherwise understood from the context and use, each of the objects described that follows that expression, and two or more different embodiments of those objects. In relation to three or more objects described, the expression “and / or” should be understood to have the same meaning unless otherwise understood from the context.
[0155] The use of the terms “include,” “includes,” “including,” “have,” “having,” “contain,” “contains,” or “containing” should generally be understood to be unrestricted and non-limiting, including these grammatical equivalents. For example, they should generally be understood not to exclude any further unmentioned elements or processes unless otherwise specifically stated or understood from the context.
[0156] It should be understood that the order of the steps or the order in which certain actions are performed is not important, insofar as the invention remains implementable. Furthermore, two or more steps or actions may be considered simultaneous.
[0157] Any and all examples or illustrative phrases used herein, such as “such as” or “including,” are intended solely to better illustrate the invention and, unless otherwise claimed, do not impose any limitation on the scope of the invention. Nothing in this specification should be construed as indicating that any unclaimed element is essential for the practice of the invention. [Examples]
[0158] The disclosures generally described herein will be more readily understood by referring to the following examples. The examples are included solely to illustrate certain aspects and embodiments of the disclosure and are not intended to limit the scope of the disclosure in any way.
[0159] Example 1: Production of rAAV composition This example describes various rAAV-containing compositions used in other examples of this disclosure.
[0160] Heterogeneically expressing rAAV was generated in human embryonic kidney (HEK) or HeLa cell producer strains. The rAAV compositions were prepared using the following formulations. [Table 1]
[0161] Example 2: Biodistribution and transduction efficiency of rAAV-containing formulations This embodiment demonstrates the successful delivery of recombinant adeno-associated virus (rAAV) expressing therapeutic gene products to various brain regions using the compositions disclosed herein.
[0162] In this embodiment, rAAV expressing CDKL5 (AAV9-SYN-CDKL5) was generated and delivered to mice lacking CDKL5.
[0163] CDKL5 deficiency disorder (CDD) is a rare neurodevelopmental disorder caused by mutations in the CDKL5 gene, which can manifest with a wide range of clinical symptoms and severity. The CDKL5 gene encodes the cyclin-dependent kinase-like 5 (CDKL5) protein, which is essential for normal brain development and function. CDD is caused by pathogenic variants in the CDKL5 gene, including deletions, shortenings, splice variants, and missense mutations. These variants can reduce the amount of functional CDKL5 protein and / or decrease its activity in neurons.
[0164] A composition was prepared containing HeLa-generated AAV9-SYN-CDKL5 and further components as shown in Table 1 of Example 1. CDKL5-deficient (Cdkl5 KO) mice between 3 and 5 weeks of age were administered 10 μL of either the control or the rAAV composition by intraventricular (ICV) injection, as shown in Table 2. The "control" group was administered either saline (group 2) or the control composition containing HEK-generated AAV9-SYN-CDKL5 (group). Wild-type C57BL / 6 mice were also used as a control (group 1). [Table 2]
[0165] Mice were sacrificed two weeks after injection, and their tissues were analyzed for the presence of vector genome (e.g., by quantitative polymerase chain reaction (qPCR)), vector RNA (e.g., using the BaseScope® assay), CDKL5 RNA (e.g., using the RNAScope® assay), or CDKL5 protein (e.g., by Western blotting).
[0166] Figure 1 shows the calculated number of genome copies (GC) per 1 μg of DNA in various brain regions (frontal cortex, caudal cortex, cerebellum, and brainstem). For all three formulations tested (groups 4, 5, and 6), the high dose (10 6 Alternatively, vector genomes with a larger GC / μg DNA (or higher) were observed in all brain regions evaluated from the brains of mice administered rAAV.
[0167] Figures 2A–2D show representative images of tissue sections with staining corresponding to RNA expression of the vector genome (as detected by BaseScope®) in mice administered with rAAV in groups 3 (Figure 2A), 4 (Figure 2B), 5 (Figure 2C), and 6 (Figure 2D). Figures 2E–2H are pie charts showing corresponding results from the quantification of BaseScope signaling (indicating transduction efficiency) in the cortex of control or rAAV formulation-administered mice from groups 3 (Figure 2E), 4 (Figure 2F), 5 (Figure 2G), and 6 (Figure 2H). Each pie chart is displayed in the upper left corner with the mouse group number for the experiment. Figure 2E shows a pie chart for mouse group 3 administered with the control composition. Figures 2F, 2G, and 2H show pie charts for groups 4, 5, and 6 administered with the rAAV formulations disclosed herein, respectively. The legend for each pie chart is located to the right of each chart and shows numbers from 0 to 4 to represent the amount of quantified genome copies (GC) / cell. The number 4 (fine dot pattern) represents >10 GC / cell; the number 3 (striped pattern) represents 4-10 GC / cell; the number 2 (medium dot pattern) represents 2-3 GC / cell; the number 1 (mesh pattern) represents 1 GC / cell; and the number 0 (blank) represents no GC / cell. As shown in Figures 2F, 2G, and 2H (corresponding to results from groups 4, 5, and 6, respectively), administration of rAAV using the formulations disclosed herein resulted in the delivery of >10 GC / cell in a significant percentage of cells in the cortex.
[0168] Figure 3 is a bar graph showing the percentage of regions in which the majority of cells have at least one genome copy. In groups 4, 5, and 6, this percentage was at least 80%.
[0169] Figures 4A-4D show representative images of tissue sections in mice administered with rAAV that exhibit staining corresponding to CDKL5 RNA expression (detectable by RNAScope®) in groups 3 (Figure 4A), 4 (Figure 4B), 5 (Figure 4C), and 6 (Figure 4D). Figure 5 shows a Western blot stained for CDKL5 protein expression in caudal cortical tissue. Staining for GADPH protein expression is shown as a loading control.
[0170] The results described in this example demonstrate that the compositions disclosed herein can be used to deliver recombinant rAAV to various brain tissues and express heterologous genes in the brain.
[0171] Example 3: Delivery of rAAV to the central nervous system by intracerebral or intrathecal injection of lumbar spine This example describes an experiment that may be used to evaluate rAAV delivery to the central nervous system using the formulations described herein, administered via the cisterna magna or lumbar intrathecal route.
[0172] A formulation containing an rAAV vector encoding a reporter gene (e.g., GFP) can be produced as described in Example 1. A certain volume of the formulation can be administered to a non-human primate (e.g., a cynomolgus monkey) by injection into the cisterna magna or by intrathecal injection into the lumbar spine. During administration, the non-human primate may be in the Trendelenburg position.
[0173] The biological distribution of rAAV can be evaluated, for example, by analyzing the amount of genome copies (GC / μg DNA) in various tissues. Delivery to the central nervous system can be evaluated by analyzing GC / μg DNA in various brain tissues. The substantial amount of genome copies across various brain tissues indicates successful delivery to the central nervous system.
[0174] The expression of reporter genes in various brain tissues and / or at the cellular level can be evaluated in tissue sections, for example, using staining or other visualization methods suitable for the reporter gene.
[0175] Example 4: Delivery of therapeutic rAAV via intracision injection rAAVs expressing genes encoding proteins associated with central nervous system disorders can be produced. Compositions containing the above rAAVs can be formulated similarly as described in Example 1. The above compositions can be delivered by intracisor injection to subjects in need (e.g., subjects diagnosed with or identified as being at risk of developing central nervous system disorders). Treatment, improvement, or prevention outcomes can be measured in the above subjects by a method appropriate to the relevant central nervous system disorder.
[0176] Example 5: Delivery of therapeutic rAAV via intralumbar-IT injection It is possible to generate rAAVs that express genes encoding proteins associated with central nervous system disorders. Compositions containing the above rAAVs can be formulated similarly as described in Example 1. The above compositions can be delivered via lumbar IT injection to subjects in need (e.g., subjects diagnosed with or identified as being at risk of developing central nervous system disorders). Treatment, improvement, or prevention outcomes can be measured in the above subjects by a method appropriate to the relevant central nervous system disorder.
[0177] Example 6: Delivery of therapeutic rAAV via intraventricular injection rAAVs expressing genes encoding proteins associated with central nervous system disorders can be generated. Compositions containing the above rAAVs can be formulated similarly as described in Example 1. The above compositions can be delivered via intracerebroventricular injection to subjects in need (e.g., subjects diagnosed with or identified as being at risk of developing central nervous system disorders). Treatment, improvement, or prevention outcomes can be measured in the above subjects by a method appropriate to the relevant central nervous system disorder.
[0178] Reference Each of the patent documents and scientific papers referred to herein in their entirety is invoked by reference for all purposes.
[0179] Equal portions This disclosure can be embodied in other specific forms without departing from its spirit and essential features. Accordingly, the embodiments described herein should be considered in all respects as illustrative rather than limiting the disclosure described herein. Various structural elements of different embodiments and steps of various disclosed methods may be used in various combinations and rearrangements, and all such modifications should be considered forms of this disclosure. The scope of this disclosure is therefore indicated by the appended claims rather than by the foregoing description, and all modifications that fall within the meaning and equivalents of the claims are intended to be encompassed therein.
[0180] Sequence List Sequence ID 1 (AAV9 amino acid sequence) MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGNGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPD PQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFP ADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDN VDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL
[0181] Sequence ID 2 (AAV2 ITR) TTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT
[0182] SEQ ID NO: 3 (SYN1 promoter) AGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGGGGTGCCTACCTGACGACCGACCCCGACCCACTGGACAAGCACCCAACCCCCATTCCCCAAATTGCGCATCCCCTATCAGAGAGGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGTGCCTTCGCCCCCGCCTGGCGGCGCGCGCCACCGCCGCCTCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCCCCCGCAAACTCCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCCGCCGGCCCAGCCGGACCGCACCACGCGAGGCGCGAGATAGGGGGGCACGGGCGCGACCATCTGCGCTGCGGCGCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCGTGCCTGAGAGCGCAG
[0183] SEQ ID NO: 4 (CBA promoter) TCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTATGCAGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCG
[0184] SEQ ID NO: 5 (SV40 polyadenylation signal) GATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAG
[0185] (Consensus Kozak sequence) GCCGCCACC
[0186] Sequence ID 7 (CMV enhancer) CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACT TGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATG
[0187] Sequence ID 8 (SV40 intron) GCTCTAAGGTAAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTCTCTCTTTTAGATTCCAACCTTTGGAACTGAT
[0188] Sequence ID 9 (Streptococcus pyogenes IdeS) DSFSANQEIRYSEVTPYHVTSVWTKGVTPPANFTQGEDVFHAPYVANQGWYDITKTFNGKDDLLCGAATAGNMLHWWFDQNKDQIKRYLEEHPEKQKINFNGEQMFDVKEAIDTKNHQLDSKLFEYFKEKAFPYLSTKHLGVFPDHVIDMFINGY RLSLTNHGPTPVKEGSKDPRGGIFDAVFTRGDQSKLLTSRHDFKEKNLKEISDLIKKELTEGKALGLSHTYANVRINHVINLWGADFDSNGNLKAIYVTDSDSNASIGMKKYFVGVNSAGKVAISAKEIKEDNIGAQVLGLFTLSTGQDSWNQTN
[0189] Sequence ID 10 (Streptococcus equi IdeZ) MKTIAYPNKPHSLSAGLLTAIAIFSLASSNITYADDYQRNATEAYAKEVPHQITSVWSKGVTPLTPEQFRYNNEDVIHAPYLAHQGWYDITKAFDGKDNLLCGAATAGNMLHWWFDQNKTEIEAYLSKHPEKQKIIFNNQELFDLKAAIDTKDSQTNSQLFNYFRDKAFPNLSA RQLGVMPDLVLDMFINGYYLNVFKTQSTDVNRPYQDKDKRGGIFDAVFTRGDQTTLLTARHDLKNKGLNDISTIIKQELTEGRALALSHTYANVSISHVINLWGADFNAEGNLEAIYVTDSDANASIGMKKYFVGINAHGHVAISAKKIEGENIGAQVLGLFTLSSGKDIWQKLS
[0190] Sequence ID 11 (AAV9 nucleic acid sequence)
[0191] Sequence ID 12 (CDKL5 brain isoform - isoform 2)
[0192] Sequence ID 13 (CDKL5 standard isoform - isoform 1)
[0193] Sequence ID 14 (CDKL5 brain isoform-isoform 2-codon optimization 1)
[0194] Sequence ID 15 (CDKL5 brain isoform - isoform 2 - codon optimization 2)
[0195] Sequence ID 16 (CDKL5 brain isoform - isoform 2 - codon optimization 3)
[0196] Sequence ID 17 (CDKL5 standard isoform - isoform 1 - codon optimized 1)
[0197] Sequence ID 18 (CDKL5 standard isoform - isoform 1 - codon-optimized 2)
[0198] Sequence ID 19 (CDKL5 standard isoform - isoform 1 - codon-optimized 3)
[0199] Sequence ID 20 (DTC350)
Claims
1. A pharmaceutical composition for use in intrathecal administration, a) Recombinant adeno-associated virus (rAAV) particles; b) A phosphate buffer or Tris buffer, wherein the phosphate or Tris is present in the pharmaceutical composition at a concentration of 5 mM to 30 mM; c) At least one monovalent salt selected from the group consisting of NaCl at concentrations of 100 mM to 250 mM and KCl at concentrations of 0.5 mM to 5 mM; d) Sorbitol in concentrations of 1% w / v to 10% w / v; and e) Poloxamer surfactant at concentrations of 0.0001% w / v to 0.001% w / v A pharmaceutical composition containing [the specified substance].
2. A pharmaceutical composition for use according to claim 1, having a pH between 7.0 and 7.
4.
3. The poloxamer surfactant is poloxamer 188 (Pluronic® F68), the pharmaceutical composition for use according to claim 1.
4. A pharmaceutical composition for use according to claim 1, further comprising one or more divalent salts.
5. The aforementioned divalent salt is MgCl 2 CaCl 2 A pharmaceutical composition for use according to claim 4, selected from the group consisting of, and combinations thereof.
6. The composition comprises (a) MgCl at a concentration between 0.5 mM and 5 mM. 2 (b) CaCl concentration between 0.5 mM and 5 mM 2 ; or a combination thereof, a pharmaceutical composition for use according to claim 5.
7. The rAAV particle is 1 × 10⁻⁶ 10 GC / mL ~ 2 x 10 14 A pharmaceutical composition for use according to claim 1, wherein the composition is present at a concentration of GC / mL.
8. The pharmaceutical composition for use according to claim 1, wherein the rAAV particles comprise an AAV capsid from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, or AAVhu37, or an AAV capsid derived from AAV9, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV11, AAV12, AAV13, AAVrh10, or AAVhu37.
9. The sorbitol is present at a concentration of 1% w / v to 10% w / v; The composition has a pH of 7.0 to 7.
4. A pharmaceutical composition for use according to claim 1.
10. The composition comprises MgCl at a concentration between 0.5 mM and 5 mM. 2 and CaCl concentrations between 0.5 mM and 5 mM 2 A pharmaceutical composition for use according to claim 9, further comprising:
11. The phosphate buffer, wherein the phosphate is present in the pharmaceutical composition at a concentration of 5 mM to 30 mM; The aforementioned NaCl in concentrations of 100 mM to 250 mM; The sorbitol in concentrations of 1% w / v to 10% w / v; and The poloxamer surfactant at a concentration of 0.0001% w / v to 0.001% w / v Includes, The composition has a pH between 7.0 and 7.
4. A pharmaceutical composition for use according to claim 1.
12. The Tris buffer, wherein the Tris is present in the pharmaceutical composition at a concentration of 5 mM to 30 mM; The aforementioned NaCl in concentrations of 100 mM to 250 mM; KCl at concentrations of 0.5 mM to 5 mM; MgCl₂ at concentrations of 0.5 mM to 5 mM; CaCl₂ at concentrations of 0.5 mM to 5 mM; The sorbitol in concentrations of 1% w / v to 10% w / v; and The poloxamer surfactant at a concentration of 0.0001% w / v to 0.001% w / v Includes, The composition has a pH between 7.0 and 7.
4. A pharmaceutical composition for use according to claim 1.
13. The pharmaceutically active composition for use according to claim 1, wherein the intrathecal administration includes intracisional, intraventricular, or lumbar administration.
14. The rAAV particles comprise an AAV capsid and a vector genome packaged within the AAV capsid, wherein the vector genome comprises CDKL5 or a coding sequence of functional fragments thereof, according to claim 1, for use.
15. The pharmaceutical composition for use according to claim 14, wherein the coding sequence of CDKL5 comprises (a) a nucleotide sequence selected from SEQ ID NOs: 12-19; or (b) a nucleotide sequence that is at least 95% identical to any one of SEQ ID NOs: 12-19.
16. The pharmaceutically acceptable composition for use according to claim 14, wherein the vector genome comprises (a) the nucleotide sequence of SEQ ID NO: 20; or (b) a nucleotide sequence that is at least 95% identical to SEQ ID NO:
20.
17. A pharmaceutical composition for use according to any one of claims 1 to 16 for treating CDKL5 deficiency disorder (CDD) in a subject, wherein the method comprises administering the pharmaceutical composition to the central nervous system of the subject.
Citation Information
Patent Citations
Regulated expression of transgenes in the mammalian central nervous system
JP2008523093A
